Skip to main content

A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.

Publication ,  Journal Article
Latzer, P; Zelba, H; Battke, F; Reinhardt, A; Shao, B; Bartsch, O; Rabsteyn, A; Harter, J; Schulze, M; Okech, T; Golf, A; Kyzirakos-Feger, C ...
Published in: Nat Commun
August 11, 2024

Current treatment outcome of patients with glioblastoma (GBM) remains poor. Following standard therapy, recurrence is universal with limited survival. Tumors from 173 GBM patients are analysed for somatic mutations to generate a personalized peptide vaccine targeting tumor-specific neoantigens. All patients were treated within the scope of an individual healing attempt. Among all vaccinated patients, including 70 treated prior to progression (primary) and 103 treated after progression (recurrent), the median overall survival from first diagnosis is 31.9 months (95% CI: 25.0-36.5). Adverse events are infrequent and are predominantly grade 1 or 2. A vaccine-induced immune response to at least one of the vaccinated peptides is detected in blood samples of 87 of 97 (90%) monitored patients. Vaccine-specific T-cell responses are durable in most patients. Significantly prolonged survival is observed for patients with multiple vaccine-induced T-cell responses (53 months) compared to those with no/low induced responses (27 months; P = 0.03). Altogether, our results highlight that the application of personalized neoantigen-targeting peptide vaccine is feasible and represents a promising potential treatment option for GBM patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Commun

DOI

EISSN

2041-1723

Publication Date

August 11, 2024

Volume

15

Issue

1

Start / End Page

6870

Location

England

Related Subject Headings

  • Treatment Outcome
  • T-Lymphocytes
  • Protein Subunit Vaccines
  • Precision Medicine
  • Middle Aged
  • Male
  • Humans
  • Glioblastoma
  • Female
  • Cancer Vaccines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Latzer, P., Zelba, H., Battke, F., Reinhardt, A., Shao, B., Bartsch, O., … Biskup, S. (2024). A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nat Commun, 15(1), 6870. https://doi.org/10.1038/s41467-024-51315-8
Latzer, Pauline, Henning Zelba, Florian Battke, Annekathrin Reinhardt, Borong Shao, Oliver Bartsch, Armin Rabsteyn, et al. “A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.Nat Commun 15, no. 1 (August 11, 2024): 6870. https://doi.org/10.1038/s41467-024-51315-8.
Latzer P, Zelba H, Battke F, Reinhardt A, Shao B, Bartsch O, et al. A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nat Commun. 2024 Aug 11;15(1):6870.
Latzer, Pauline, et al. “A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.Nat Commun, vol. 15, no. 1, Aug. 2024, p. 6870. Pubmed, doi:10.1038/s41467-024-51315-8.
Latzer P, Zelba H, Battke F, Reinhardt A, Shao B, Bartsch O, Rabsteyn A, Harter J, Schulze M, Okech T, Golf A, Kyzirakos-Feger C, Kayser S, Pieper N, Feldhahn M, Wünsche J, Seitz C, Hadaschik D, Garbe C, Hauser T-K, la Fougère C, Biskup D, Brooke D, Parker D, Martens UM, Illerhaus G, Blumenthal DT, Merrell R, Lorenzo LS, Hidvégi M, de Robles P, Kebir S, Li WW, Li VW, Williams M, Miller AM, Kesari S, Castro M, Desjardins A, Ashley DM, Friedman HS, Wen PY, Neil EC, Iwamoto FM, Sipos B, Geletneky K, Zender L, Glas M, Reardon DA, Biskup S. A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nat Commun. 2024 Aug 11;15(1):6870.

Published In

Nat Commun

DOI

EISSN

2041-1723

Publication Date

August 11, 2024

Volume

15

Issue

1

Start / End Page

6870

Location

England

Related Subject Headings

  • Treatment Outcome
  • T-Lymphocytes
  • Protein Subunit Vaccines
  • Precision Medicine
  • Middle Aged
  • Male
  • Humans
  • Glioblastoma
  • Female
  • Cancer Vaccines